

# EUROPEAN CURRICULUM VITAE FORMAT



## PERSONAL INFORMATION

Name **VALERIA RAIA**

Address

Telephone

Fax

E-mail [raia@unina.it](mailto:raia@unina.it)

Nationality

Date of birth

## WORK EXPERIENCE

- Dates (from – to) **2017: HABILITATION TO FULL PROFESSOR OF PEDIATRICS**  
**2015: CONFIRMED ASSOCIATE PROFESSOR OF PEDIATRICS AT UNIVERSITY FEDERICO II, DEPARTMENT OF MEDICAL TRANSLATIONAL SCIENCES SECTION OF PEDIATRICS, NAPLES**  
**2010: NATIONAL CERTIFICATION ASSOCIATE PROFESSOR OF PEDIATRICS**  
**2009: TEAM LAEDER OF REGIONAL CYSTIC FIBROSIS CENTRE AT UNIVERSITY FEDERICO II, DPT OF MEDICAL TRANSLATIONAL SCIENCES SECTION OF PEDIATRICS, NAPLES**  
**1999-2006: RICERCATORE PEDIATRICO AT UNIVERSITY FEDERICO II OF NAPLES, DPT OF PEDIATRICS**  
**1981-1999: MEDICAL ASSISTANT AT UNIVERSITY FEDERICO II OF NAPLES, DPT OF PEDIATRICS**

- Name and address of employer University of Naples, Federico II-AOU 5 Pansini Street, 80131-Naples
  - Type of business or sector Health Care Company /School of Medicine and Surgery
  - Occupation or position held Chief Regional Cystic Fibrosis Pediatric Unit
- Main activities and responsibilities Full-time Employer as Professor of Pediatrics at University Federico II of Naples, Italy

## EDUCATION AND TRAINING

- Dates (from – to) 1980-1983: Specialization in Pediatrics  
1973-1979: Degree in Medicine and Surgery
- Name and type of organisation providing education and training University of Medicine and Surgery, Naples
- Principal subjects/occupational skills covered Medicine and Surgery, Pediatrics, Cystic Fibrosis and other Chronic pulmonary diseases, pediatrics Gastroenterology
  - Title of qualification awarded Degree in Medicine and Surgery, Specialization in Pediatrics
- Level in national classification (if appropriate)

**PERSONAL SKILLS  
AND COMPETENCES**

*Acquired in the course of life and career  
but not necessarily covered by formal  
certificates and diplomas.*

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

ENGLISH

- Reading skills
- Writing skills
- Verbal skills

GOOD

GOOD

GOOD

**SOCIAL SKILLS  
AND COMPETENCES**

*Living and working with other people, in  
multicultural environments, in positions  
where communication is important and  
situations where teamwork is essential  
(for example culture and sports), etc.*

As part of Cystic Fibrosis, from November 1998 to November 2001, she was a Member of the Council of Italian Cystic Fibrosis Society. Previously Member of the following Committee of Cystic Fibrosis Italian Group

1. Italian Registry of Cystic Fibrosis
2. Clinical Research Unit
3. Cystic Fibrosis Italian Registry

She cooperated in the achievement of the electronic medical record for the management of italian patients affected by CF (CAMILLA).

From 2004 to 2007 she was Secretary of Cystic Fibrosis Italian Society.

From 2014 to 2016 she was a Member of of the Council of Italian Cystic Fibrosis Society.

Currently She is President of the Italian Cystic Fibrosis Society (2017-2019))

**ORGANISATIONAL SKILLS  
AND COMPETENCES**

*Coordination and administration of  
people, projects and budgets; at work, in  
voluntary work (for example culture and  
sports) and at home, etc.*

Coordination and continuity of health care of paediatric and adult services in Campania Region for patients affected by Cystic Fibrosis residing in Campania by applying a structured multidisciplinary transition program.

Cooperation for training activities regarding respiratory rehabilitation in the Region.

Scientific Consultant for Regional Cystic Fibrosis Association since 1996.

**TECHNICAL SKILLS  
AND COMPETENCES**

*With computers, specific kinds of  
equipment, machinery, etc.*

Training and management of human resources in healthy performance.

Work with software and didactic training packets for students and professionals in health care.

Technical skills for medical aids and devices available for respiratory assistance (spirometer, stationary bicycle ergometer, pulmonary ventilator, multiple- breath washout)

**ARTISTIC SKILLS  
AND COMPETENCES**

*Music, writing, design, etc.*

**OTHER SKILLS**

**AND COMPETENCES**

*Competences not mentioned above.*

DRIVING LICENCE(S)

Category B driving license

## ADDITIONAL INFORMATION

### MAIN MULTICENTRIC STUDIES:

- "A MULTICENTER RANDOMIZED DOUBLE BLIND EUROPEAN STUDY TO EVALUATE THE LONG -TERM EFFECT OF ANTI-PSEUDOMONAS VACCINE ON PREVENTION OF PSEUDOMONAS AERUGINOSA COLONIZATION IN PATIENTS WITH CYSTIC FIBROSIS" KV9909– FUNDED BY ORPHAN EUROPE/ BERNA 2001-2004
- "A MULTICENTER RANDOMIZED DOUBLE BLIND NATIONAL STUDY TO EVALUATE THE LONG -TERM EFFECT OF BIPHOSPHONATES ON PREVENTION OF OSTEOPOROSIS-OSTEOPENIA IN PATIENTS WITH CYSTIC FIBROSIS " 02A001 – FUNDED BY TELETHON 2001-2004
- "AN ITALIAN PROJECT #16/2004 "NASAL POLYPS OF CYSTIC FIBROSIS PATIENTS AS AN EX VIVO MODEL TO STUDY INFLAMMATION AND ITS MODULATION VIA THE INHIBITION OF THE P38 MAP - KINASE PATHWAY: IMPLICATIONS FOR THE THERAPY" (PROGETTO MULTICENTRICO)- FUNDED BY ITALIAN CYSTIC FIBROSIS RESEARCH FOUNDATION 2004-2005
- LOCAL SCIENTIFIC COORDINATOR OF PROJECT FUNDED BY THE ITALIAN MINISTRY OF UNIVERSITY PRIN " POLIPI NASALI DI PAZIENTI CON FIBROSI CISTICA COME MODELLO EX VIVO PER LO STUDIO DELL'INFIAMMAZIONE E DELLA SUA MODULAZIONE ATTRAVERSO L'INIBIZIONE DELLA P-38 MAP-CHINASI: IMPLICAZIONI PER LA TERAPIA" " ANNO 2004 - PROT. 2004051178\_003
- " AN ITALIAN MULTICENTER STUDY ON COMMUNITY-ACQUIRED MRSA AND HOSPITAL-ACQUIRED MRSA IN CYSTIC FIBROSIS PATIENTS: A STUDY REGARDING ANTIBIOTIC SUSCEPTIBILITY, EPIDEMIOLOGY, NATURAL HISTORY AND CLINICAL RELEVANCE." 2/2006 - FUNDED BY ITALIAN CYSTIC FIBROSIS RESEARCH FOUNDATION 2006
- "AN ITALIAN MULTICENTER STUDY ON PREVENTIVE CONTROL OF PSEUDOMONAS AERUGINOSA FIRST INFECTION" –FUNDED BY ITALIAN CYSTIC FIBROSIS RESEARCH FOUNDATION 2007-2009
- " AN ITALIAN MULTICENTER RANDOMIZED DOUBLE BLIND STUDY FOR PREVENTION OF PULMONARY EXACERBATIONS IN CHILDREN WITH CYSTIC FIBROSIS, THROUGH THE MODIFICATION OF INTESTINAL MICROFLORA" 20/2006 - FUNDED BY ITALIAN CYSTIC FIBROSIS RESEARCH FOUNDATION 2006-2008
- " A RANDOMIZED, SINGLE BLIND, CONTROLLED TRIAL OF INHALED GLUTATHIONE VERSUS PLACEBO IN PATIENTS WITH CF". COD FARM7K7XZB – FUNDED BY ITALIAN PHARMACEUTICAL AGENCY (AIFA) 2010 –2013
- " A MULTICENTER EUROPEAN OPEN-LABEL, RANDOMIZED, PHASE 3 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AZTREONAM LYSINE FOR INHALATION VERSUS TOBRAMYCIN NEBULISER SOLUTION IN AN INTERMITTENT AEROSOLIZED ANTIBIOTIC REGIMEN IN PATIENTS WITH CYSTIC FIBROSIS" GS-US-205-01 10 FUNDED BY GILEAD SCIENCES, INC. 2025 1ST AVENUE, SUITE 800 2008 -2013
- NATIONAL COORDINATOR OF PROJECT FUNDED BY THE ITALIAN MINISTRY OF UNIVERSITY PRIN " STUDIO DELLA CORRELAZIONE FRA DIFETTO GENETICO, RESISTENZA ALL'INSULINA E INFIAMMAZIONE IN FIBROSI CISTICA: IMPLICAZIONI PER LA DIAGNOSI E IL TRATTAMENTO " ANNO 2010 – 2012 PROT. 2008RMJB3A.
- A MULTICENTER RANDOMIZED DOUBLE BLIND STUDY ON PROBIOTICS IN CYSTIC FIBROSIS - FUNDED BY CYSTIC FIBROSIS FOUNDATION THERAPEUTICS USA, 2010 COMPLETED
- PROJECT #15/2012 " THE HEME-OXYGENASE 1 (HO-1) AS MODULATOR OF CYSTIC FIBROSIS LUNG DISEASE" 2012-2014 FUNDED BY ITALIAN CYSTIC FIBROSIS RESEARCH FOUNDATION
- PROJECT TELETHON GGP12128 " THE HEME-OXYGENASE 1 (HO-1) AS MODULATOR OF CYSTIC FIBROSIS LUNG DISEASE", 2012-2014
- COORDINATOR OF PROJECT FUNDED BY EUROPEAN INSTITUTE FOR CYSTIC FIBROSIS RESEARCH, ONLUS FOUNDATION "RESTORATION OF CFTR FUNCTION IN PATIENTS WITH CYSTIC FIBROSIS

CARRYING THE F508DEL-CFTR MUTATION," 2013 COMPLETED

- COORDINATOR OF PROJECT FUNDED BY EUROPEAN INSTITUTE FOR CYSTIC FIBROSIS RESEARCH, ONLUS FOUNDATION "A NOVEL TREATMENT OF CYSTIC FIBROSIS ACTING ON-TARGET: CYSTEAMINE PLUS EPIGALLOCATECHIN GALLATE FOR THE AUTOPHAGY-DEPENDENT RESCUE OF CLASS II-MUTATED CFTR", 2014 COMPLETED

Participating for years in numerous multicentric studies both nationally and internationally about CF complications.

**1. TEACHING DUTIES**

Since 1999 Prof. Raia has attended students with practical classes and seminars. Once become a researcher, she carried out didactic activity both in the Medicine and Surgery degree course and in the Pediatric Postgraduate School at Federico II Medical School in Naples.

Professor in the following courses:

1. Pediatrics at Medical school of Medicine, University of Naples Federico II
2. Pediatrics at the Physioterapy School of Medicine, University of Naples Federico II
3. Bronchopneumology at the Post Graduate School of Pediatrics, University of Naples Federico II
4. Pediatrics at Medical School of Medicine, University of Campobasso (Molise)
5. Pediatrics at the Post Graduate School of Physiatry
6. Pediatrics at the Post Graduate School of Ortopic
7. Pediatrics at the Post Graduate School of Logopedy

Tutor of students of the School of Medicine at the University of Naples Federico II. Involvement in Educational Programs for Pediatricians, Physioterapists and Dietitians.

**2. RESEARCH ACTIVITY**

Her interest in Cystic Fibrosis spans many aspects, i.e. association between genotype and phenotype, standardization of diagnostic and therapeutic procedures, mechanisms for disease variability, modulation of disease phenotype by probiotics, development of new antiinflammatory therapies, identification of inappropriate epithelial apoptosis; characterization of duodenal chronic inflammation; modulation of inflammatory response in ex vivo organ culture models. In the last years, her clinical activity was mainly focused at developing new mutation-specific pharmacological therapies to correct the basic defect in cystic fibrosis as well as at implementing a new predictor test of individual patient's responsiveness to treatment finalized to a patient-based personalized approach to therapy.

Prof. Raia made important contribution to the identification of new therapeutic strategies to control inflammation in Cystic Fibrosis. She was the first to demonstrate that the inhibition of p38 MAP kinase may be of potential interest in CF therapy and that probiotic administration may reduce the number of pulmonary exacerbations and control intestinal inflammation. She implemented the ex vivo culture model of nasal polyp mucosal explants from patients with Cystic Fibrosis as a tool to study pathogenic mechanisms of inflammation and the appropriate ways of modulation. In collaboration with the research group of L. Maiuri and G. Kroemer, she identified defective autophagy as a key pathogenic event in CF, and discovered how genetic or pharmacological modulation of autophagy can allow F508del-CFTR to traffic to and reside at plasma membrane of CF bronchial epithelial cell lines as well as primary brushed nasal cells from CF patients. Very recently, Dr. Raia in collaboration with Dr. Maiuri, Dr Kroemer and Dr. Mehta, provided the first clinical evidence that a pharmacological approach can revert to normal sweat chloride levels and reduce inflammation in patients homozygotes and heterozygous for the F508del-CFTR mutant enrolled in two different phase II clinical trials at the Pediatric Cystic Fibrosis Centre of Naples.

Besides CF, her research activity focused on the study of the pathogenesis of celiac disease and on the modulation of the innate immune response to gliadin peptides, as well as on the regulation of lactase expression in adult-type hypolactasia.

She has authored over 120 papers on international peer reviewed journals covering all aspects of CF. **Impact factor 531; IH 35**

- *to use my personal data according to law 196/2003.*
- *I declare to conduct clinical trials according to GCP*

Naples, 29/ April/ 2019